Login to Your Account

Keryx Makes Next Move, Files Zerenex NDA

By Marie Powers
Staff Writer

Thursday, August 8, 2013
As expected, New York-based Keryx Biopharmaceuticals Inc. submitted a new drug application (NDA) for Zerenex (ferric citrate coordination complex) in the initial indication of treating elevated serum phosphorus levels, or hyperphosphatemia, in patients with chronic kidney disease (CKD) on dialysis.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription